Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography. by Zanchin, Christian et al.
RESEARCH ARTICLE
Progression of cardiac allograft vasculopathy
assessed by serial three-vessel quantitative
coronary angiography
Christian Zanchin1, Kyohei Yamaji1, Carolin Rogge1, Dorothea Lesche2,
Thomas Zanchin1, Yasushi Ueki1, Stephan Windecker1, Paul Mohacsi1, Lorenz Ra¨ber1,
Vilborg Sigurdardottir1*
1 Department of Cardiology, Bern University Hospital, Bern, Switzerland, 2 Institute of Clinical Chemistry,
Bern University Hospital, Bern, Switzerland
* vilborgs@gmail.com
Abstract
Background
The purpose of the present study was to assess the short- and long-term progression of car-
diac allograft vasculopathy (CAV) using serial 3-vessel quantitative coronary angiography
(QCA).
Methods
CAV progression was assessed using serial 3-vessel QCA analysis at baseline, 1-year and
long-term angiographic follow-up (8.5±3.7 years) after heart transplantation. The change in
minimal lumen diameter (MLD) and percent diameter stenosis (%DS) was serially assessed
within matched segments. Patients were graded according to the ISHLT-CAV classification
and grouped as ISHLT-CAV0 and ISHLT-CAV1-3. The primary endpoint was mean change
in MLD and %DS.
Results
A total of 41 patients and 520 matched segments were available for serial 3-vessel QCA.
Overall, MLD decreased non-significantly from baseline to 1-year follow-up and significantly
from 1-year to the long-term angiographic follow-up (Δ-0.08mm/year [95%CI -0.11 to -0.05],
P<0.001). %DS increased significantly from baseline to 1-year (Δ+0.96%/year [95%CI 0.04
to 1.88], P = 0.041) and from 1-year to long-term angiographic follow-up (Δ+0.61%/year
[95%CI 0.33 to 0.88], P<0.001). ISHLT-CAV1-3 at 1 year and at long-term angiographic
follow-up was observed in 22% and 61%, respectively. Between baseline and long-term
angiographic follow-up, a significant reduction in MLD was observed within both groups
without a significant difference in the reduction between the two groups (ISHLT-CAV0:
median -0.49mm [IQR -0.54 to -0.43] vs. ISHLT-CAV1-3: median -0.40mm [IQR -0.44 to
-0.35], P = 0.4).
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Conclusion
The current data suggest that QCA can’t predict CAV beyond 1 year, but, QCA affirmed that
CAV progresses to a similar extent in patients who do not develop visual CAV during long-
term follow-up.
Background
Cardiac allograft vasculopathy (CAV) has become one of the most important cause of long-
term mortality after heart transplantation (HTx) [1]. CAV is characterized by a concentric
and diffuse proliferation of the coronary arterial intima, resulting in thickening and progres-
sive luminal narrowing [2]. Because the modification in immunosuppressive therapy
may delay or even cause CAV regression, the early detection of CAV is of high clinical inter-
est [3–7].
The current guidelines recommend annual or biannual coronary angiography for detection
and surveillance of CAV [5]. CAV is classified on a visual assessment of coronary angiographic
findings and graft function according to the International Society for Heart and Lung Trans-
plantation (ISHLT) classification [5]. When using the ISHLT-classification, the incidence of
CAV is approximately 8% at 1 year, 30% at 5 years, and 50% at 10 years [1]. However, concern
remains in the ability of coronary angiography to detect accurately the early stages and pro-
gression of CAV [8]. Intravascular ultrasound (IVUS) studies have found a coronary intimal
thickening in up to 80% of patients already during the first year after HTx without angio-
graphic signs of CAV and angiographically silent progression of CAV predicts long-term mor-
bidity and mortality after cardiac transplantation [9,10].
Quantitative coronary angiography (QCA) has been used for many years in clinical
research to assess the luminal diameter of arteries. It can readily survey the entire coronary
vascular system on the coronary angiographies. While QCA makes quantification of coronary
atherosclerosis progression possible [11,12], no studies with serial 3-vessel QCA have been
conducted to determine CAV progression. Therefore, the aim of this study was to assess CAV
progression by using serial 3-vessel QCA at baseline, at 1 year, and at long-term angiographic
follow-up after HTx.
Methods
Study population
This is a retrospective observational cohort study including 83 HTx recipients who underwent
heart transplantation between January 1994 and October 2015 at the University Hospital of
Bern. Follow-up angiography 1 year after HTx was available in 77 patients and was used to
assess CAV risk factors. For the purpose of the serial 3-vessel QCA analyses, we excluded
patients without baseline angiography, 1 year follow-up angiography, or long-term follow-up
angiography (n = 36). Finally, we enrolled 41 patients in the serial 3-vessel QCA analyses set. A
detailed patient flow is shown in Fig 1.
The study complied with the Declaration of Helsinki and the study was approved by the
Cantonal Ethics Committee of Bern (CEC 186/14). All patients provided written informed
consent. None of the transplant donors were from a vulnerable population and all donors or
next of kin provided written informed consent that was freely given.
CAV by serial three-vessel QCA
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Fig 1. Flow chart. CAV indicates cardiac allograft vasculopathy; FUP, follow-up; QCA, quantitative coronary angiography; ISHLT,
International Society of Heart and Lung Transplantation.
https://doi.org/10.1371/journal.pone.0202950.g001
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Coronary angiography assessment
CAV was classified by a retrospective review of all coronary angiographic and echocardio-
graphic studies at 1 year, and at latest angiographic follow-up after HTx, based on the ISHLT
guidelines [5] as follows: ISHLT-CAV0 indicates no visually detectable angiographic lesion;
ISHLT-CAV1 (mild) indicates angiographic left main <50%, or primary vessel with a maxi-
mum lesion of<70%, or any branch stenosis <70% (including diffuse narrowing) without
allograft dysfunction; ISHLT-CAV2 (moderate) indicates angiographic left main<50%, a sin-
gle primary vessel 70%, or isolated branch stenosis 70% in branches of 2 systems, without
allograft dysfunction; and ISHLT-CAV3 (severe) indicates angiographic left main 50%, or
two or more primary vessels with 70% stenosis, or isolated branch stenosis 70% in all 3
systems, or ISHLT-CAV1 or ISHLT-CAV2 with allograft dysfunction (defined as left ventricu-
lar ejection fraction 45% with the presence of regional wall motion abnormalities). For the
current analysis, we defined the presence of CAV as a status ISHLT-CAV1 and we grouped
the study population in ISHLT-CAV0 and ISHLT-CAV1-3. We conducted follow-up and
angiographic assessment until April 2016.
Quantitative coronary angiography assessment
Standard biplane angiographic images were obtained after administration of intra-coronary
nitroglycerin (100–300 μg) with a frame rate of 15/second. Each coronary segment was
recorded in at least two orthogonal views. All angiographies were analyzed at the angiographic
core laboratory at the University Hospital of Bern by two independent clinicians (CZ, KY),
and a third clinician in case of disagreement (LR), who were blinded to any clinical data. All
three major epicardial vessels including all side branches with a reference vessel diameter
(RVD) of>1.5mm were assessed by QCA at baseline, at 1-year, and at long-term angiographic
follow-up after HTx by using similar projections whenever possible. For this purpose, seg-
ments of the coronary vessels were divided into subsegments according to the modified Amer-
ican Heart Association/American College of Cardiology (AHA/ACC) [9] classification (Fig 2).
QCA analysis was done by using the QangioXA version 7.3 (Medis Medical Imaging Systems,
Leiden, the Netherlands). Minimal lumen diameter (MLD), RVD, segment length and maxi-
mal percent diameter stenosis [%DS, calculated by (1 –MLD/RVD) x 100] within the subseg-
ments were assessed. In the case of interim revascularization, the revascularized vessel was
analyzed prior to the revascularization, whereas the non-revascularized vessel segments were
analyzed at the long-term angiographic follow-up. The change of all variables was derived for
each segment as outcome (long-term angiographic follow-up and 1 year follow-up) minus out-
come (1 year follow-up and baseline). The primary angiographic endpoint was mean change
in MLD and %DS. Analysis was performed to determine the MLD and %DS change within the
two groups (ISHLT-CAV0 vs. ISHLT-CAV1-3) 1 year after HTx and at long-term angiographic
follow-up.
Immunosuppression therapy and rejection score
The induction immunosuppressive therapy consisted of azathioprine 5 mg/kg and 1000 mg of
methylprednisolone. Antithymocyte globulin (4–5 mg/kg) therapy was introduced within 12
hours post-transplant and thereafter tailored by CD3 cell count. A calcineurin inhibitor (CNI)
based immunosuppressive therapy was initiated as a standard maintenance therapy. In case of
progressive impairment of renal function, everolimus (ERL) was initiated already within the
first month after HTx. Other reasons for switching to ERL were progressive CAV and skin
malignancy or side effects. Switching to ERL therapy was a decision that was left to the
CAV by serial three-vessel QCA
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Fig 2. Serial 3-vessel quantitative coronary angiography analysis. This figure shows the serial quantitative coronary angiography analysis within
matched regions of all coronary artery segments at baseline, at 1 year follow-up, and at latest available angiographic follow-up. Coronary artery
segments were classified according to the modified AHA/ACC classification. MLD indicates minimal lumen diameter; %DS, percent diameter
stenosis.
https://doi.org/10.1371/journal.pone.0202950.g002
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discretion of the experienced transplant cardiologist. The general targeted ERL trough concen-
tration (C0) was 6–8 ng/mL and 8–14 ng/mL for tacrolimus (TAC) with a concomitant therapy
of prednisone and mycophenolate mofetil (MMF) or azathioprine. Endomyocardial biopsy
(EMB) specimens were graded according to the 2005 ISHLT classification for acute cellular
rejection (ACR) as 0R = 0, 1R = 1, 2R = 2, and 3R = 3 [13]. Severe Total Rejection Score (TRS)
was defined as number of ACR 2R divided by the total numbers of biopsies. Antibody-medi-
ated rejection (AMR) was diagnosed in the EMB specimens according to standardized histo-
pathologic signs of AMR and, if indicated, with immunohistochemistry to confirm AMR. No
immunohistochemistry positive EMBs or allograft rejections with hemodynamic compromise
were observed.
Clinical and demographic data
Clinical and angiographic data were retrieved by a retrospective review of all patient charts
or database. The cardiovascular risk factors were monitored according to local guidelines.
Hypertension was defined as systolic blood pressure 140 mmHg and/or diastolic blood
pressure 90 mmHg. Hypercholesterolemia was defined as total cholesterol 5.2 mmol/L.
MDRD (Modification of Diet in Renal Disease) glomerular filtration rate (shown as GFR; cre-
atinine shown as Cr) was calculated by using the following formula: GFR = 186 x Serum-Cr
-1.154 x age -0.203 x (0.742 if patient was female).
Acetylsalicyclic acid (ASA) therapy was continued after HTx in most patients with previous
CAD or as indicated after percutaneous coronary intervention (PCI). After HTx, all patients
received statin therapy. Ezetimibe was added in case of insufficient lipid lowering effect. In
case of high-risk cytomegalovirus (CMV) serologic status (i.e., donor positive and recipient
negative), HTx recipients received ganciclovir or valganciclovir CMV prophylaxis adapted to
individual kidney function for 6 months. Pre-emptive CMV treatment was given in all other
patients throughout the follow-up period.
Statistical analysis
Continuous variables for patient-level data are expressed as median with interquartile range or
mean ± standard deviation (SD). Categorical variables are expressed as number and percent-
age. Patients were stratified into two groups according to the presence or absence of ISHLT-
CAV at 1 year and at latest angiographic follow-up. Comparisons between the groups regard-
ing risk factors of CAV were performed by using the χ2 test. All hypotheses tested were 2-tailed
and a p-value<0.05 was considered statistically significant.
QCA outcomes were recorded for segments per patient at baseline, at 1 year, and at long-
term angiographic follow-up. For each segment, we computed the absolute change from base-
line to 1-year, from baseline to long-term angiographic follow-up, and from 1-year to long-
term angiographic follow-up. Patient-level outcomes and their changes were generated by
using generalized linear mixed effect model. Wilcoxon rank sum test was used to compare the
changes of parameters between baseline, 1 year, and long-term angiographic follow-up. To
assess the subsegment-level data of the QCA analysis and its associations of all clinical vari-
ables, including the ISHLT-CAV grading score, a linear regression analysis was used that took
into account a random effect of patient-level data.
Statistical analyses were performed with the use of R version 3.2.3 (R Foundation for Statis-
tical Computing).
CAV by serial three-vessel QCA
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Results
Baseline characteristics
The donor and recipient characteristics of the study cohort are summarized in Table 1. The
study population consisted of 77 patients (57 males), with a mean recipient age at HTx of 46.6
(±15.7) years. ERL-based therapy was administered in 41 (53%) and TAC-based therapy in 36
(47%) patients. The leading cause of HTx was dilated cardiomyopathy (n = 36; 47%), followed
by ischemic cardiomyopathy (n = 27; 35%). During follow-up, 14 patients underwent PCI.
Thirteen underwent PCI due to CAV and 1 patient due to fistula from the left anterior
descending artery to the right ventricle. No patient had echocardiographic allograft dysfunc-
tion (defined as LVEF 45% with the presence of regional wall motion abnormalities) at latest
follow-up.
Serial 3-vessel quantitative coronary angiography analyses
A total of 520 native coronary artery segments (12.7 segments per patient) at baseline (median
0.14 [0.12 to 0.16] years after HTx) were matched with the corresponding segments at 1 year
follow-up (median 1.17 [1.14 to 1.20] years after HTx) and at long-term angiographic follow-
up (median 8.61 [8.24 to 8.99] years after HTx). Fig 3 shows the overall mean change of MLD
and %DS from baseline to 1 year follow-up, and from 1 year follow-up to long-term angio-
graphic follow-up. MLD decreased non-significantly from baseline to 1 year follow-up (Δ-0.04
mm/year [95% CI -0.17 to -0.08], p = 0.49), and significantly from 1 year follow-up to long-
term angiographic follow-up (Δ-0.08 mm/year [95% CI -0.11 to -0.05], p< 0.001). %DS
increased significantly from baseline to 1 year follow-up (Δ+0.96%/year [95% CI 0.04 to 1.88],
p = 0.041), and from 1 year follow-up to long-term angiographic follow-up (Δ+0.61%/year
[95% CI 0.33 to 0.88], p< 0.001).
Table 2 represents the serial 3-vessel QCA results between the ISHLT-CAV groups. On cor-
onary angiography at 1 year, 32 patients (78%) were graded as ISHLT-CAV0, whereas 9
patients (22%) were graded as ISHLT-CAV1-3 [ISHLT CAV1, n = 9 (100%); ISHLT-CAV2,
n = 0 (0%); ISHLT-CAV3, n = 0 (0%)]. At long-term angiographic follow-up, 16 patients
(39%) were graded as ISHLT-CAV0, whereas 25 patients (61%) were graded as ISHLT-CAV1-3
[ISHLT-CAV1, n = 18 (72%); ISHLT-CAV2, n = 7 (28%); ISHLT-CAV3, n = 0 (0%)]. A reduc-
tion in MLD was observed within both groups between baseline and 1 year follow-up, and
between baseline and long-term angiographic follow-up. The reduction in MLD between the
two groups did not differ at 1 year (ISHLT-CAV0: median -0.04 mm [IQR -0.10 to 0.02] vs.
ISHLT-CAV1-3: median -0.07 mm [IQR -0.12 to -0.02], p = 0.8) and during long-term angio-
graphic follow-up (ISHLT-CAV0: median -0.49 mm [IQR -0.54 to -0.43] vs. ISHLT-CAV1-3:
median -0.40 mm [IQR -0.44 to -0.35], p = 0.4) (Fig 4). Patients who developed ISHLT-
CAV1-3 during long-term follow-up showed a significantly higher baseline %DS (ISHLT-
CAV0: median 13.6% [IQR 13.2 to 14.1] vs. ISHLT-CAV1-3: median 15.9% [IQR 15.6 to 16.3],
p = 0.01), and at long-term angiographic follow-up %DS (ISHLT-CAV0: median 15.9% [IQR
15.3 to 16.6] vs. ISHLT-CAV1-3: median 21.0% [20.5 to 21.5], p< 0.001). The increase in %DS
between baseline and long-term angiographic follow-up was significantly higher in the
ISHLT-CAV1-3 group (ISHLT-CAV0: median 2.3% [IQR 1.7 to 2.9] vs. ISHLT-CAV1-3:
median 5.1% [IQR 4.6 to 5.5], p = 0.02).
Cardiac allograft vasculopathy risk factors
Table 3 shows baseline clinical characteristics according to the presence or absence of ISHLT-
CAV1-3 at latest angiographic follow-up. On latest coronary angiography, 39 patients (51%)
CAV by serial three-vessel QCA
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Table 1. Baseline clinical characteristics.
HTx recipients
(n = 77)
Recipient age at transplantation (years) 46.6 ± 15.7
Donor age (years) 43.4 ± 13.2
Recipient (male) 57 (74)
Primary cause of HTx
Dilated cardiomyopathy 36 (47)
Ischemic cardiomyopathy 27 (35)
Arrhythmogenic right ventricular cardiomyopathy 5 (6)
Hypertrophic cardiomyopathy 2 (3)
Valvular heart disease 2 (3)
Other causes 5 (6)
Cardiac risk factors
BMI (kg/m2) 24.6 ± 4.7
Hypertension 30 (39)
Systolic blood pressure (mmHg) 130 ± 17
Diastolic blood pressure (mmHg) 78 ± 12
HbA1c 5.8 ± 0.7
Active smoker 9 (12)
eGFR (mL/min) 65.2 ± 27.3
CMV serology, donor positiv/recipient negativ 21 (27)
CMV infection 29 (38)
Severe TRS  2R 0.040 ± 0.052
Lipids
Hypercholesterolemia 37 (48)
Total cholesterol (mmol/L) 5.3 ± 1.5
HDL cholesterol (mmol/L) 1.6 ± 0.5
LDL cholesterol (mmol/L) 3.2 ± 1.2
Triglycerides (mmol/L) 2.2 ± 1.5
Medication
ACEi / ARB 54 (70)
Beta Blocker 21 (27)
Calcium channel blocker 24 (31)
Aspirin or Clopidogrel 51 (66)
Statin 77 (100)
Ezetimibe 19 (25)
Immunosuppressive Regimes
Everolimus, MMF, Prednisone 24 (31)
Everolimus, MMF 13 (17)
Everolimus, Prednisone 3 (4)
Everolimus, AZA, Prednisone 1 (1)
Tacrolimus, MMF 18 (23)
Tacrolimus, MMF, Prednisone 12 (16)
Tacrolimus, Prednisone 4 (5)
Tacrolimus, AZA 2 (3)
Echocardiography
LVEF (%) 62 ± 6
Categorical variables are shown as number (%). Continuous variables are shown as mean ± SD
HTx, heart transplantation; BMI, body mass index; eGFR, estimated glomerular filtration rate; CMV,
cytomegalovirus; TRS, total rejection score; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACEi,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MMF, Mycophenolate mofetil; AZA,
Azathioprin; LVEF, left ventricular ejection fraction
Other causes: congenital heart disease (1 patient), giant cell myocarditis (1 patient), Naxos-Syndrome (1 patient),
myofibrillar myopathy (1 patient), biventricular heart failure of unknown etiology (1 patient)
https://doi.org/10.1371/journal.pone.0202950.t001
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were graded as ISHLT-CAV0, whereas 38 patients (49%) were graded as ISHLT-CAV1-3
[CAV1, n = 25 (66%); CAV2, n = 12 (32%); CAV3, n = 1 (3%)]. ISHLT- CAV1-3 was signifi-
cantly associated with eight factors: higher recipient age (45.0 years [26.0–54.0] vs. 55.5 years
[42.5–61.5]; p = 0.01); higher donor age (38.5 years [31.0–49.7] vs. 49.0 years [39.0–57.5];
p = 0.009); CAD before HTx (9 (23%) vs. 18 (47%); p = 0.046); lower eGFR (70.2 ml/min
[52.1–87.4] vs. 54.8 ml/min [39.4–66.8]; p = 0.005); higher LDL cholesterol (2.5 mmol/l [2.1–
3.7] vs. 3.2 mmol/l [2.5–3.9]; p = 0.08); higher triglyceride (1.5 mmol/l [1.1–2.0] vs. 2.3 mmol/l
[1.3–3.8]; p = 0.01); severe TRS 2 (0.00 [0.00–0.05] vs. 0.05 [0.00–0.09]; p = 0.005); and male
donor (24 (62%) vs. 32 (84%); p = 0.07). Higher max %DS was significantly associated with
five factors: higher recipient age (48.0 years [22.0–56.5] vs. 53.0 years [41.2–60.0]; p = 0.04);
higher HbA1c (5.5 [5.3–5.8] vs. 5.8 [5.6–6.1]; p = 0.004); lower eGFR (68.2 ml/min [56.9–89.2]
vs. 53.8 ml/min [39.4–69.3]; p = 0.002); higher LDL cholesterol 2.5 mmol/l [2.1–3.6] vs. 3.2
mmol/l [2.5–4.0]; p = 0.09); and severe TRS 2 (0.00 [0.00–0.06] vs. 0.04 [0.00–0.09];
p = 0.03). There were no significant differences between the two groups regarding the adher-
ence to immunosuppressive medications and cardiovascular medication including ERL, TAC,
MMF, azathioprine, prednisone, ACE inhibitor/ARB, statin, and ezetimibe.
Discussion
The four main findings of this study can be summarized as follows. First, patients without
visual signs of CAV during follow-up showed similar MLD loss compared with ISHLT-CAV1-
3 patients. Secondly, MLD loss between baseline and 1-year after HTx did not predict CAV
progression beyond 1 year. Thirdly, baseline %DS was higher in patients who were developing
ISHLT-CAV1-3 at latest angiographic follow-up. Fourth, risk factors of CAV according to the
ISHLT-CAV classification were in line with the risk factors associated with the QCA analyses.
Fig 3. Serial 3-vessel quantitative coronary angiography analysis. Box-plot representation of minimal lumen diameter and maximal percent diameter stenosis at
baseline (median 0.14 years [0.12 to 0.16], at 1 year (median 1.17 years [1.14 to 1.20]) and at long-term angiographic follow-up (median 8.61 years [8.24 to 8.99])
after HTx. Lower and upper box edges are the quartiles and thick line is the median.
https://doi.org/10.1371/journal.pone.0202950.g003
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Use of serial three-vessel QCA to assess cardiac allograft vasculopathy
progression
The present study made it possible to assess short- and long-term progression of CAV with the
current standard of visual ISHLT-CAV classification and the serial 3-vessel QCA analyses
within all segments of the three coronary arteries. The advantage of using QCA is that it
detects subtle changes of luminal narrowing. IVUS studies have shown that approximately
80% of patients already show a thickening of the coronary intima within the first year after
HTx [9]. Of note, most of those patients generate the intimal thickening without angiographi-
cal signs of CAV. Importantly, the most rapid rate of intimal thickening occurs during the first
Table 2. QCA analysis of serial angiography at baseline, 1 year and long-term follow-up after heart transplantation.
All patients At 1 year p-value At long-term follow-up p-value
ISHLT-CAV0 ISHLT-CAV1-3 ISHLT-CAV0 ISHLT-CAV1-3
Number of patients 41 32 9 16 25
Number of segments 520 408 112 204 316
Number of segments per
patient
12.7 12.8 12.4 12.8 12.6
Reference Vessel Diameter (mm)
Baseline 3.10 [3.06 to 3.15] 3.10 [3.05 to 3.15] 3.12 [3.02 to 3.22] 0.91 3.13 [3.06 to 3.21] 3.09 [3.02 to 3.15] 0.74
1-year 3.04 [2.97 to 3.12] 2.97 [2.89 to 3.06] 3.29 [3.13 to 3.44] 0.26 3.09 [2.97 to 3.21] 3.01 [2.91 to 3.10] 0.72
Latest FUP 2.67 [2.61 to 2.72] 2.65 [2.58 to 2.71] 2.73 [2.61 to 2.85] 0.67 2.58 [2.50 to 2.67] 2.72 [2.65 to 2.79] 0.43
Segment Length (mm)
Baseline 36.1 [35.4 to 36.9] 36.0 [35.1 to 36.8] 36.6 [35.0 to 38.3] 0.81 34.9 [33.7 to 36.1] 36.9 [35.9 to 37.8] 0.41
1-year 36.7 [36.0 to 37.4] 36.1 [35.3 to 36.9] 38.8 [37.3 to 40.3] 0.31 34.6 [33.5 to 35.7] 38.0 [37.1 to 38.9] 0.12
Latest FUP 33.7 [33.1 to 34.3] 33.6 [33.0 to 34.3] 33.8 [32.5 to 35.1] 0.93 31.5 [30.6 to 32.4] 35.1 [34.3 to 35.8] 0.06
Total Segment Length (mm)
Baseline 456.4 [446.7 to
466.1]
456.7 [445.6 to
467.9]
455.1 [434.1 to
476.1]
0.96 444.9 [429.2 to
460.5]
463.8 [451.2 to
476.3]
0.53
1-year 463.7 [454.8 to
472.7]
459.0 [448.8 to
469.2]
480.5 [461.2 to
499.8]
0.51 441.2 [427.0 to
455.4]
478.1 [466.8 to
489.5]
0.17
Latest FUP 426.4 [418.1 to
434.7]
428.0 [418.5 to
437.5]
420.6 [402.6 to
438.5]
0.8 401.6 [388.6 to
414.7]
442.2 [431.8 to
452.6]
0.11
Minimal Lumen Diameter (mm)
Baseline 2.53 [2.49 to 2.57] 2.55 [2.50 to 2.59] 2.48 [2.39 to 2.56] 0.64 2.61 [2.54 to 2.67] 2.48 [2.43 to 2.54] 0.34
1-year 2.47 [2.41 to 2.53] 2.44 [2.37 to 2.51] 2.59 [2.46 to 2.71] 0.5 2.56 [2.47 to 2.66] 2.41 [2.34 to 2.49] 0.41
Latest FUP 2.10 [2.05 to 2.14] 2.09 [2.04 to 2.15] 2.11 [2.01 to 2.21] 0.94 2.11 [2.04 to 2.19] 2.09 [2.03 to 2.15] 0.87
Δ in MLD (1 year-BL) -0.06 [-0.10 to -0.02] -0.11 [-0.15 to -0.06] 0.10 [0.02 to 0.19] 0.15 -0.04 [-0.10 to 0.02] -0.07 [-0.12 to -0.02] 0.8
Δ in MLD (FUP-BL) -0.43 [-0.47 to -0.40] -0.45 [-0.49 to -0.41] -0.38 [-0.45 to -0.30] 0.56 -0.49 [-0.54 to -0.43] -0.40 [-0.44 to -0.35] 0.4
Diameter Stenosis (%)
Baseline 15.0 [14.7 to 15.3] 14.7 [14.4 to 15.0] 16.3 [15.7 to 17.0] 0.13 13.6 [13.2 to 14.1] 15.9 [15.6 to 16.3] 0.01
1-year 16.0 [15.67 to 16.4] 15.6 [15.2 to 16.0] 17.6 [16.9 to 18.4] 0.12 15.1 [14.5 to 15.6] 16.7 [16.2 to 17.1] 0.16
Latest FUP 19.0 [18.6 to 19.5] 18.2 [17.7 to 18.8] 21.9 [20.9 to 22.9] 0.04 15.9 [15.3 to 16.6] 21.0 [20.5 to 21.5] <0.01
Δ in %DS (1 year-BL) 1.0 [0.7 to 1.3] 0.9 [0.6 to 1.3] 1.3 [0.7 to 2.0] 0.72 1.4 [1.0 to 1.9] 0.7 [0.3 to 1.1] 0.43
Δ in %DS (FUP-BL) 4.0 [3.6 to 4.4] 3.6 [3.1 to 4.0] 5.6 [4.8 to 6.4] 0.15 2.3 [1.7 to 2.9] 5.1 [4.6 to 5.5] 0.02
Patient-level outcomes derived as the median (mm) and interquartile range. P-values using generalized linear mixed effect model taking random effects of patient-level
data into account. QCA indicates quantitative coronary angiography; BL, baseline; FUP, follow-up; MLD, minimal lumen diameter; %DS, percent diameter stenosis; Δ,
difference;
Change was derived at the level of segments.
https://doi.org/10.1371/journal.pone.0202950.t002
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year after HTx, followed by a slower rate of intimal thickening. Furthermore, a rapid progres-
sion of maximal intimal thickness of>0.5 mm during the first year after HTx has been shown
to be predictive of angiographic CAV after five years [14] and of increased risk of all-cause
mortality and myocardial infarction [10]. Due to a lack of standardized predictive value of
lumen change between baseline and 1 year, such cut-off values are not available for QCA in
the current analysis. In contrast to our expectation, the reduction in MLD from baseline to
long-term angiographic follow-up did not differ between patients with ISHLT-CAV0 and
ISHLT-CAV1-3 (ISHLT-CAV0: median -0.49 mm [IQR -0.54 to -0.43] vs. ISHLT-CAV1-3:
median -0.40 mm [IQR -0.44 to -0.35], p = 0.4). A failure in QCA to detect a significant lumen
loss between baseline and 1 year, as an indirect indicator of the vessel wall thickening, might
be influenced by an expansion of the external elastic membrane leading to a preservation of
the luminal area without angiographic signs of CAV [15,16]. Hence, since angiography only
depicts the lumen contour, QCA could not identify early intimal thickening by narrowing of
the lumen area in patients who developed ISHLT-CAV1-3 during long-term follow-up. Fur-
thermore, the similarity in the lumen loss between the two groups during long-term follow-up
might be caused by a diffuse longitudinal and concentric narrowing of the coronary artery ves-
sel wall that decreases MLD even though no angiographic signs of CAV were apparent. Fur-
thermore, RVD decreased over time in a similar way like MLD, which indicates that the lumen
narrowed in the coronary artery tree without visual plaque stenosis. This pathophysiological
mechanism of CAV progression has been previously described in histopathology studies [17–
19]. Hence, diffuse concentric intimal thickening and narrow points of constriction may be
Fig 4. Quantitative angiographic analysis. Box-plot representation of the per-patient mean angiographic change in minimal lumen diameter (minimal lumen
diameter 1 year—minimal lumen diameter baseline and minimal lumen diameter latest angiographic follow-up—minimal lumen diameter baseline) from
coronary artery segments that were serially assessed and matched. The analysis is stratified according to absence (n = 16) or presence (n = 25) of ISHLT-CAV at 1
year, and at latest angiographic follow-up (median 8.61 years [8.24 to 8.99]). Lower and upper box edges are the quartiles and thick line is the median. A horizontal
reference line at change = 0 is drawn.
https://doi.org/10.1371/journal.pone.0202950.g004
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overlooked with coronary angiography, and applying the ISHLT classification might underes-
timate the CAV progression since it is mainly defined by stenotic plaques. As shown in our
study, %DS expressed the vascular plaque stenosis in accordance to the ISHLT-CAV classifica-
tion, which shows a significant difference in %DS at baseline and during long-term angio-
graphic follow-up between the ISHLT-CAV groups.
Arora et.al. [7] demonstrated a significantly reduced CAV progression, and significantly
less coronary intimal thickening, in patients treated with de novo everolimus-based therapy
and early calcineurin inhibitor withdrawal, compared to the calcineurin inhibitor control
group irrespective of donor disease in a matched IVUS examination at baseline and 12 months
after HTx. In our cohort of 41 patients, 53% of the patients received everolimus-based and cal-
cineurin inhibitor-free immunosuppressive therapy at latest angiographic follow-up, 42% of
whom switched therapies within the first month after HTx. Hence, the use of potent immuno-
suppressive drugs in our cohort such as mycophenolate mofetil and everolimus might have
decelerated CAV progression. In our cohort, including matched serial three vessel QCA analy-
ses, 78% had no visual signs of CAV one year after HTx, a finding possibly influenced by the
early everolimus therapy after HTx. However, during long-term angiographic follow-up there
was no significant difference in the presence of CAV between the everolimus-based group
compared with the tacrolimus-based group. Furthermore, the prevalence of CAV detected by
Table 3. Baseline clinical characteristics in patients with and without ISHLT-CAV at latest follow-up.
ISHLT-CAV0 at latest follow-up
n = 39
ISHLT-CAV1-3 at latest follow-up
n = 38
p-value Lower max %DS
n = 39
Higher max %DS
n = 38
p-value
Recipient profile
Age (years) 45.0 [26.0–54.0] 55.5 [42.5–61.5] 0.01 48.0 [22.0–56.5] 53.0 [41.2–60.0] 0.04
Male 28 (72) 29 (76) 0.85 27 (69) 30 (79) 0.48
Body mass index, kg/m2 24.2 [22.5–26.4] 24.1 [20.6–27.9] 0.83 23.81 [21.5–26.2] 24.3 [21.6–28.1] 0.29
CAD before HTx 9 (23) 18 (47) 0.046 11 (28) 16 (42) 0.3
Hypertension 15 (38) 15 (39) 1 13 (33) 17 (45) 0.43
HbA1c (%) 5.6 [5.4–5.8] 5.7 [5.4–6.1] 0.12 5.5 [5.3–5.8] 5.8 [5.6–6.1] 0.004
Active Smoker 5 (13) 4 (11) 1 4 (10) 5 (13) 0.97
eGFR (ml/min) 70.2 [52.1–87.4] 54.8 [39.4–66.8] 0.005 68.2 [56.9–89.2] 53.8 [39.4–69.3] 0.002
Hypercholesteremia 16 (41) 21 (55) 0.31 18 (46) 19 (50) 0.91
Total cholesterol (mmol/L) 4.5 [4.0–5.8] 5.2 [4.5–6.2] 0.13 4.9 [4.0–5.8] 5.2 [4.5–6.2] 0.19
HDL cholesterol (mmol/L) 1.6 [1.2–2.1] 1.5 [1.2–1.8] 0.49 1.5 [1.2–1.9] 1.6 [1.3–1.9] 0.57
LDL cholesterol (mmol/L) 2.5 [2.1–3.7] 3.2 [2.5–3.9] 0.08 2.5 [2.1–3.6] 3.2 [2.5–4.0] 0.09
Triglyceride (mmol/L) 1.5 [1.1–2.0] 2.3 [1.3–3.8] 0.01 1.8 [1.1–2.4] 2.0 [1.3–2.8] 0.52
CMV, donor pos./ recipient neg. 8 (21) 13 (34) 0.27 10 (25) 11 (29) 0.94
CMV infection 12 (31) 17 (45) 0.3 12 (31) 17 (45) 0.3
Severe TRS 2R 0.00 [0.00–0.05] 0.05 [0.00–0.09] 0.005 0.00 [0.00–0.06] 0.04 [0.00–0.09] 0.03
LVEF-FUP (%) 65.0 [60.0–65.0] 60.0 [60.0–65.0] 0.07 65.0 [60.0–65.0] 60.0 [60.0–65.0] 0.19
LVEDP (mmHg) 12.5 [8.5–17.0] 11.5 [6.0–15.0] 0.25 13.0 [8.0–17.5] 11.0 [6.0–14.0] 0.13
Donor profile
Age (years) 38.5 [31.0–49.7] 49.0 [39.0–57.5] 0.009 42.0 [33.0–52.8] 48.0 [36.2–55.5] 0.16
Male 24 (62) 32 (84) 0.07 25 (64) 31 (82) 0.19
Values shown are median [lower to upper quartile] or number (%), p<0.05 was considered statistically significant; CAD, coronary artery disease; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoproteins; LDL, low-density lipoproteins; MLD, minimal lumen diameter; RVD, reference vessel diameter; CMV,
cytomegalovirus; TRS, total rejection score; LVEF, left ventricular ejection fraction; FUP, follow-up, LVEDP, left ventricular end diastolic pressure.
https://doi.org/10.1371/journal.pone.0202950.t003
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coronary angiography at 1, 5, and 10 years after HTx is approximately 10–20%, 35–50%, and
50–60% [9], respectively. This finding is in line with our data, which report the prevalence of
CAV at 1 year, and at a mean follow-up time of 9 years in 22% and 61% of patients, respec-
tively. Of note, only 1 patient had visual sign of donor transmitted CAD at baseline.
Risk factors of cardiac allograft vasculopathy
Several risk factors have been linked with CAV development including increasing donor age,
donor history of hypertension, pre-transplant CAD, and cardiovascular risk factors [20]. To
further validate the QCA method in our cohort, we assessed the risk factors of CAV with %DS
and the ISHLT-CAV classification. Risk factors of CAV associated with maximal %DS and the
ISHLT-CAV classification were similar, including recipient age, HbA1c, eGFR, and severe
TRS 2R. Even though QCA is a more sensitive method than the visual assessment in identi-
fying subtle changes of the coronary artery tree, it could not identify additional risk factors
compared to the ISHLT-CAV classification. Surprisingly, the ISHLT-CAV classification addi-
tionally detected donor age, donor male, CAD before HTx, and triglycerides as CAV risk fac-
tors. Delgado et al. [21] also showed that donor age, CMV infection, and presence of cellular
acute rejection 2R are predictors of CAV. In our study, CMV infection was not associated
with CAV, which is in conflict with recent large cohort studies [21,22]. In a review by Braga
et al. [23] the inconsistency of the CAV risk factors was suggested to be influenced by different
CAV assessment methods, classification, and observation time.
The results of our single-centre retrospective study have to be interpreted in the light of
some limitations. First, the lack of serial angiographies resulted in a limited sample size. Sec-
ond, patients with more side branches, but with a reference diameter>1.5mm, could have a
lower MLD not reflective of CAV. Nevertheless, baseline MLD between the two groups
showed no significant difference in MLD and RVD, thus representing comparable groups.
Furthermore, there was no significant difference between the two groups regarding the mea-
sured segments per patient and segment length. Consequently, the results should be regarded
as exploratory.
Conclusions
Mean lumen diameter loss between baseline and 1-year after heart transplantation as assessed
by QCA in all coronary artery segments did not predict CAV progression in the long-term.
There was no difference in MLD loss over time within the coronary tree between ISHLT-
CAV0 and ISHLT-CAV1-3 patients as assessed by QCA, suggesting a similar progression of
CAV independently of the ISHLT-CAV classification.
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